ORGO - Organogenesis Holdings Inc

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures and markets solutions for the advanced wound care and surgical and sports medicine markets in the United States. The company is headquartered in Canton, Massachusetts.

52W High

$6.71

52W Low

$2.47

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.76

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

12.32

EV/EBITDA (<8 favorable)

228.77

EV/Revenue (<3 favorable)

1.70

P/S (TTM) (<3 favorable)

1.48

P/B (<3 favorable)

2.72

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

46.69%

Institutions (25–75% balanced)

55.13%

Shares Outstanding

126,858,000

Float

55,470,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

429,531,000

Gross Profit (TTM)

320,331,000

EPS (TTM)

-0.14

Profit Margin (>10% good)

-0.02%

Operating Margin (TTM) (higher better)

-0.11%

ROE (TTM) (>15% strong)

-0.03%

EPS YoY (Quarterly) (>10% good)

3.50

Revenue YoY (Quarterly) (>8% good)

-0.22

Momentum

Bearish momentum

Value

0.1107

0.1180

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025